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Abstract The multidrug resistance protein MRP has been 
shown to mediate the transport of glutathione S-conjugates 
across membranes. In this study we demonstrate that the 
glutathione S-conjugate of the diuretic drug ethacrynic acid, 
which is an efficient inhibitor of glutathione S-transferases, is a 
high-affinity substrate and inhibitor of the glutathione S- 
conjugate pump associated with MRP. This implies that 
ethacrynic acid may modulate drug resistance of tumor cells 
not only by inhibiting glutathione S-transferase activity, but also 
by inhibiting the export of drug conjugates from the cell by 
MRP. 
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1. Introduction 
GSTs in drug resistance in cell lines [16], in colon tumor 
xenografts [17] and in a phase I clinical trial to improve the 
efficacy of the alkylating drug thiotepa [18]. Moreover, EA 
inhibited the GST-catalyzed conjugation of GSH with the 
clinically important alkylating drug chlorambucil [19]. EA 
can modulate drug resistance in several ways. (i) EA decreases 
intracellular GSH levels. (ii) Both EA and its conjugate (EA- 
SG) are reversible inhibitors of GSTs of the ~x, ~t and n sub- 
classes [20,21]. (iii) EA can also bind covalently to GSTn 
[20,21]. 
Here we show that GS-EA is an efficient substrate of the 
GS-X pump associated with MRP-expression and that it can 
inhibit dinitrophenylglutathione (DNP-SG) uptake in mem- 
brane vesicles containing MRP. This implies that EA may 
modulate drug resistance in tumor cells not only by decreasing 
GST activity, but also by inhibiting the export of drug con- 
jugates from the cell by MRP. 
The human multidrug resistance-associated protein MRP 
confers resistance to natural product drugs by lowering their 
intracellular concentration [1-3]. Although the resistance spec- 
trum of MRP resembles that of MDR1 P-glycoprotein (Pgp), 
there are several indications that the mechanism of drug trans- 
port by MRP is fundamentally different from that of Pgp. 
(i) Increased expression of MRP is associated with increased 
ATP-dependent transport of glutathione S-conjugates (GS-X) 
into isolated membrane vesicles [4~6] and from living cells [7]. 
(ii) MRP requires GSH to export anti-cancer drugs and ar- 
senite out of the cell [8]. (iii) Drug transport by MRP is 
relatively insensitive to classic reversal agents of Pgp-mediated 
multidrug resistance (MDR), such as verapamil and cyclo- 
sporin (analogues) [2,3], but is modulated by inhibitors of 
organic anion transport, such as probenecid and sulfinpyra- 
zone [6,7,9,10]. These data suggest that MRP is a GS-X pump 
[I1] and link MRP-mediated MDR to drug resistance asso- 
ciated with GSH and GSH S-transferases (GSTs) [5,8,12]. 
GSTs are a family of isoenzymes with broad substrate spe- 
cificity that catalyze the conjugation of the tripeptide GSH to 
many xenobiotics [13]. Conjugation to GSH improves the 
solubility of these substrates and may facilitate their removal 
from the cell by GS-X pumps. In addition, GSTs have been 
suggested to serve as intracellular sinks and carrier proteins 
for certain hydrophobic and electrophilic molecules [13-15]. 
Increased cellular amounts of GST isoenzymes are associated 
with resistance against alkylating agents and doxorubicin [12]. 
The diuretic drug ethacrynic acid (EA) is a potent inhibitor of 
the activity of GSTs and has been used to study the role of 
*Corresponding author. Fax: (31) (20) 669 1383. 
2. Materials and methods 
2.1. Chemicals and enzymes 
Dinitrophenyl[glycine-2-3H]glutathione (DNP-[3H]SG) with specific 
activity of 370 GBq/mmol was a gift from Dr. R.P.J. Oude Elferink 
(Academic Medical Center, University of Amsterdam). The radioac- 
tive conjugate of EA [2,3-dichloro-4-(2-methylene-l-oxobutyl)phenox- 
y]acetic acid was chemically synthesized from [14C]EA (0.555 GBq/ 
mmol; Amersham, Bucks, UK) and GSH (Sigma Chemical Co., St. 
Louis, MO) and purified by high-performance liquid chromatography 
(HPLC) as described previously [20,21]. 4-Glutathionyl cyclophospha- 
mide was synthesized byadding 2 mmol 4-hydroperoxycyclophospha- 
mide (kind gift from Dr. J. Pohl, Asta Medica, Frankfurt am Main, 
Germany) to 20 mmol GSH in 400 ml of 70 mM phosphate buffer, 
pH 7.0. After incubation for 2 h at 25°C the 4-glutathionyl cyclophos- 
phamide was purified from the mixture by HPLC as described [22]. 
GST isoenzymes were purified from rat liver (GSTI-1 and GST3-3) 
and rat kidney (GST 7-7) by affinity chromatography with S-hexyl- 
glutathione-Sepharose 6B and chromatofocussing [23]. Purity was 
confirmed by SDS-polyacrylamide g l electrophoresis, oelectric 
focussing and HPLC [23,24]. 
2.2. Cell lines and yeast strains 
SI(MRP) is a subline of the human on-small cell lung cancer cell 
line SW-1573/S1 that overexpresses MRP 15-fold [3,8]. This cell line 
was obtained by transfection of S1 ceils with an expression vector 
containing MRP cDNA and a neomycin-resistance gene and selection 
with Geneticin (G418) [3]. GLC4/ADR is a subline of the human 
small cell lung cancer cell line GLC4 that overexpresses MRP 51~ 
100-fold [3,5]. This cell line was isolated by a multistep selection of 
GLC4 cells up to 1152 nM doxorubicin [3,5]. The yeast strain 
DTY168 (Mato~, ura3-52, ycflA::his, leu2-3, -112, his6) [25] was 
used for heterologous expression of the MRP cDNA [6], 
2.3. Preparation of membrane vesicles 
Membrane vesicles from human lung cancer cells were prepared as 
described by Miiller et al. [5]. Cell monolayers of S1 and SI(MRP) 
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(109 cells) were washed twice, scraped into ice-cold phosphate-buf- 
fered saline (PBS) and collected by centrifugation at 1000×g for 10 
rain at 4°C, GLC4 and GLC4/ADR cells were harvested by centrifu- 
gation and washed twice with PBS. The cell pellets were resuspended 
in 50 ml of a hypotonic buffer (1 mM Tris-HC1, pH 7.0) and stirred 
gently for 2 h on ice in the presence of 400 units of recombinant 
Serratia marcescens nuclease (Benzonase, grade I, protease-free; 
Merck Darmstadt, Germany) and the protease inhibitors phenyl- 
methylsulfonyl fluoride (1 mM), leupeptide (2 ~tg/ml), pepstatin (1 
gg/ml), and aprotinin (2 gg/ml). The cell lysate was centrifuged at 
100000×g for 30 min at 4°C, and the resulting pellet was suspended 
in 10 ml of isotonic TS buffer (0.25 M sucrose, 10 mM Tris-HC1, pH 
7,4) and homogenized with a Dounce B homogenizer (glass/glass, 
tight pestle, 30 strokes) in the presence of Benzonase (800 units) 
and protease inhibitors. The crude membrane fraction was layered 
on top of a 38% (w/v) sucrose solution in 5 mM Tris-HEPES (pH 
7.4) and centrifuged in a Beckman SW41 rotor at 280 000 × g for 2 h 
at 4°C. The turbid layer at the interface was collected, diluted to 20 ml 
with TS buffer, and centrifuged at 100 000 × g for 30 min at 4°C. The 
resulting pellet was suspended in 400 gl of TS buffer. Vesicles were 
formed by passing the suspension 30 times through a 25-gauge needle 
with a syringe. The membrane vesicles were finally frozen in liquid 
nitrogen and stored at -70°C until used in transport assays. Protein 
concentration was determined using a Bio-Rad protein assay (Bio- 
Rad, Richmond, CA). 
Membrane vesicles from S. cerevisiae cells were prepared as de- 
scribed by Tommasini et al. [6]. In short, cells were grown overnight 
in SD medium (0.7% (w/v) yeast nitrogen base without amino acids 
(Difco), 0.5% (w/v) casamino acids (Difco), 2% (w/v) glucose) to an 
OD600 of approx. 10. The cells were harvested by centrifugation, 
washed with water, and resuspended in the original culture volume 
in 1.1 M sorbitol, 20 mM Tris-HC1 (pH 7.6), 1 mM dithiotreitol, 
containing 57 units of lyticase (Sigma, St. Louis) per ml. After incu- 
bation for 90 min at 30°C, spheroplasts were collected by centrifuga- 
tion. The spheroplasts were resuspended in homogenization buffer 
(1.1 M glycerol, 50 mM Tris-ascorbate (pH 7,4), 5 mM EDTA, 
1.5% (w/v) polyvinylpyrrolidone K30 (Fluka, Buchs, Germany) and 
disrupted in a dounce homogenizer. Unbroken cells and cell debris 
were removed by centrifugation at 4000×g for 10 min. The super- 
natant was centrifuged at 150 000 x g for 45 min. The pellet was re- 
suspended at an OD600 of 4 in suspension buffer (1.1 M glycerol, 50 
mM Tris-Mes (pH 7.4), 1 mM EDTA), frozen in liquid nitrogen, and 
stored at -70°C. 
2.4. Vesicle uptake studies 
Transport of DNP-[3H]SG and [14C]EA-SG was measured by a 
rapid filtration technique using nitrocellulose filters (0.45 gm pore 
size; Schleicher and Schuell) presoaked in TS buffer. Membrane ves- 
icles from lung cancer cells were rapidly thawed and pre-incubated for 
15 s at 25°C for DNP-[3H]SG uptake experiments, or at 37°C for 
127 
[14C]EA-SG uptake experiments. The reaction was started by adding 
the labeled substrate. The reaction buffer was TS supplemented with 
4 mM ATP, 10 mM MgC12, 10 mM creatine phosphate and 100 gg/ml 
creatine kinase (Boehringer Mannheim). The final volume was 110 gl. 
Samples of 20 gl (Fig. 1) or 33 gl (other experiments) were taken at 
the indicated time points and diluted in 1 ml of ice-cold TS buffer. 
This solution was applied to the pre-soaked filters and rinsed with 5 ml 
of TS buffer. In control experiments for DNP-[aH]SG transport ATP 
was omitted; in control experiments for [14C]EA-SG transport ATP 
was replaced by AMP-PNP (4 raM). Each filter was placed in liquid 
scintillation fluid, and radioactivity was measured by liquid scintilla- 
tion counting. 
Uptake of [14C]EA-SG in yeast microsomal vesicles was measured 
essentially as described above with the following modifications. One 
part of the vesicles was mixed with six parts of transport solution (0.4 
M glycerol, 100 mM KC1, 20 mM Tris-Mes, pH 7.4) and incubated at 
25°C in the presence of 5 mM MgATP and 2 gM [taC]EA-SG. Sam- 
ples of 100 gl were taken at the indicated time points. 
3. Results 
We examined the ability of EA-SG and of a metabolite of 
the alkylating drug cyclophosphamide, i.e. 4-glutathionyl cy- 
clophosphamide (4-GS-CP) [22], to inhibit the ATP-depen- 
dent transport of DNP-[aH]SG into plasma membrane vesi- 
cles isolated from the MRP-overexpressing lung cancer cell 
line SI(MRP) [3]. The ATP-dependent uptake of DNP-  
[3H]GS in vesicles of SI(MRP) cells was approx. 8-fold great- 
er than in vesicles from parental S1 cells (i.e. 8.3 + 3.6-fold; 
n = 4), in agreement with previous experiments with these cells 
[5]. Among the compounds tested, EA-SG was the most po- 
tent inhibitor of DNP-[aH]SG transport (Table 1). EA-SG 
inhibited transport 2000-fold more effectively than probenecid 
and 400-fold more effectively than sulfinpyrazone. Inhibition 
of transport by 4-GS-CP also occurred, but only at relatively 
high concentrations (Table 1). 
The transport of EA-SG was characterized using 14C-la- 
beled EA-SG. Vesicles of SI(MRP) cells showed time- and 
MgATP-dependent accumulation of [14C]EA-SG (Fig. 1A). 
The transport rate correlated with the level of MRP. In the 
drug-selected lung cancer cell line GLC4/ADR,  containing 
greater amounts of MRP than SI(MRP) [3], the transport 
rate was also higher (Fig. 1B). The transport rates in 
SI(MRP) and GLC4/ADR were 7- and 20-fold higher than 
Table 1 
Effect of inhibitors on ATP-dependent uptake of DNP-[ZH]SG (10 gM) into plasma membrane vesicles from SI(MRP) cells a 
Inhibitor Relative uptake (%)¢ 
- 100 
GSH (1 mM) 83 + 4 
Probenecid (10 mM) -17 + 13 
(1 mM) 55 + 4 
Sulfinpyrazone (2 mM) 9 + 5 
(400 gM) 56 +_ 5 
GSH S-conjugate of ethacrynic acid (100 gM) -17 + 7 
(10 gM) 4 + 30 
(1 gM) 61 + 40 
(100 nM) 95 + 12 
(10 nM) 120 + 14 
4-Glutathionyl cyclophosphamide (1 mM) 44 + 21 
(100 IxM) 73+ 11 
AMP b (4 mM) -4  _+ 7 
aSI(MRP) membrane vesicles were incubated at 25°C for 3 min as described in Section 2. 
bATP was replaced by AMP. 
~ATP-dependent uptake = uptakeATp--Uptake-ATP. Values are means + S.D. of 3 independent experiments, with each determination (+ and -ATP) 
performed in triplicate. 
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Fig. 1. Time course of uptake of [14C]EA-SG into plasma membrane vesicles from human lung cancer cells overexpressing MRP (SI(MRP) 
and GLC4/ADR cells), and microsomal vesicles from yeast cells expressing MRP (DTY168(MRP) cells). Uptake of 10 ~tM [14C]EA-SG into 
SI(MRP) (A), GLC4/ADR (B), or of 2 I.tM [14C]EA-SG into DTY168(MRP) (C) vesicles in the presence of MgATP (O) or of MgAMP ([]). 
ATP-dependent transport (e) = valUeSATp--valUeSAMP. Means of three independent experiments are shown, with each determination performed 
in duplicate. 
in the respective parental cell lines S1 and GLC4 (results from 
parental cell lines not shown). The Km value calculated for 
[14C]EA-SG transport in membrane vesicles from SI(MRP) 
cells was 28+4 ~tM, with a Vm~ of 505 +68 pmol mg 
protein -1 rain -1 (Figs. 2 and 3). These values are similar to 
those for DNP-[3H]SG [5,6], suggesting that EA-SG and 
DNP-SG are transported with equal efficiencies by MRP. Un- 
modified EA (10 ~tM) was taken up into membrane vesicles of 
lung cancer cells, but uptake was independent of MgATP and 
was not increased in the MRP-overexpressing cell lines, indi- 
cating that unmodified EA is not a substrate of MRP (results 
not shown). 
We recently showed that expression of human MRP cDNA 
in a S. cerevisiae mutant strain with a disrupted YCF1 gene 
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Fig. 2. Concentration dependence of ATP-dependent uptake of 
[14C]EA-SG into membrane vesicles from SI(MRP) cells. SI(MRP) 
vesicles were incubated for 3 min at 37°C. ATP-dependent transport 
(O) =valuesATp--valuesAMp. eans of 3 independent experiments, 
with each determination (+ATP and +AMP) performed in dupli- 
cate. 
(strain DTY168 [25]) was able to restore the uptake of DNP- 
SG in microsomal vesicles isolated from DTYI68 [6]. Vesicles 
from DTY 168 cells expressing MRP cDNA (strain 
DTY168(MRP) [6]) also showed time- and MgATP-depend- 
ent uptake of [14C]EA-SG (Fig. 1C). The transport rate was 
11-fold higher than in DTY168 cells (results not shown). The 
apparent Km value was 5 ~tM for EA-SG in microsomal ve- 
sicles from DTY168(MRP) cells, with a Vm~ of 1250 pmol 
mg protein -1 min -1. 
The uptake of [14C]EA-SG into SI(MRP) membrane vesi- 
cles was inhibited by probenecid, sulfinpyrazone and oxidized 
glutathione (GSSG), but not by reduced glutathione (GSH) 
(Table 2). EA-SG has been shown to inhibit GST-catalyzed 
conjugation reactions [15-21]. However, addition of purified 
rat GST isoenzymes 1-1, 3-3 and 7-7 (10 ~tM) had no effect on 
the time-dependent uptake of [14C]EA-SG into membrane ves -  
Table 2 
Effect of inhibitors on ATP-dependent uptake of [14C]EA-SG (10 
~tM) into plasma membrane vesicles from SI(MRP) cells a
Inhibitor Relative uptake (%)b 
- 100 
GSH (1 mM) 95 
GSSG (1 raM) 60 
Probenecid (1 mM) 53 
Sulfinpyrazone (400 [.tM) 44 
~SI(MRP) membrane vesicles were incubated at 37°C for 3 min as 
described in Section 2. 
bATP-dependent uptake = uptakenTP--uptakenMe. Values are means 
of 2 independent experiments, with each determination performed in 
triplicate. 
icles (results not shown). We conclude that the binding of EA- 
SG to GSTs [20,21] does not influence the transport of this 
conjugate by MRP. 
4.  D iscuss ion  
Our data show that EA-SG is a substrate and a high-affin- 
ity inhibitor of the GS-X pump associated with MRP expres- 
sion. This implies that EA may modulate cellular drug resist- 
ance not only by decreasing GST activity, but also by 
inhibiting the export of drug conjugates from cells by MRP. 
Consistent with this, EA increased the accumulation of the 
fluorescent dye calcein acetoxy methyl ester in tumor cells 
containing increased amounts of MRP [10]. Furthermore, re- 
sistance against EA in a colon cancer cell line has been asso- 
ciated with increased GSH, GST and MRP mRNA levels, 
suggesting that all three components may act together in 
EA resistance [26]. 
The Km value for EA-SG transport in vesicles from lung 
cancer cells or from yeast cells expressing MRP is in the same 
range as for DNP-SG (i.e. 5-30 IxM). Also, our inhibition 
experiments with DNP-[aH]SG suggest that EA-SG and 
DNP-SG are transported with equal efficiencies by MRP. 
However, [14C]EA-SG gave almost no background binding 
to nitrocellulose filters, which is a problem with DNP- 
[aH]SG, as well as with another model substrate of GS-X 
pumps, LTC4. [14C]EA-SG may therefore be the most suitable 
substrate for routine screening of compounds for their capac- 
ity to inhibit transport by MRP. 
There has been considerable speculation i  the literature on 
the transport mechanism of ABC transporters, uch as P-gly- 
coprotein or MRP. One of the possibilities discussed is that 
these transporters affect drug distribution in an indirect fash- 
ion, e.g. by influencing another transporter or by affecting ion 
transport. The fact that MRP is able to transport EA-SG 
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both in the physiological context of the mammalian mem- 
brane and in the unphysiological context of a yeast membrane 
provides support to the interpretation that MRP directly 
transports EA-SG over the membrane itself. 
It is unclear whether, and to what extent, the inhibition of 
GS-X transport by GS-EA may have contributed to the mod- 
ulatory effect of ethacrynic acid on drug resistance in cell lines 
and patients [16-19]. The biochemical effects of ethacrynic 
acid on cells are diverse, and also include depletion of GSH 
levels, inhibition/reaction with GSTs and probably other en- 
zymes containing sulfhydryl groups [20,21]. However, since 
GS-EA is effective in inhibiting GS-X transport at concentra- 
tions that are well below those toxic to cancer cell lines in 
tissue culture [16,27], the inhibition of transport by GS-EA 
may be relevant in vivo. 
4-GS-CP inhibited the GS-X pump activity associated with 
MRP expression only at relatively high concentrations. This 
conjugate is therefore unlikely to be a substrate of MRP un- 
der physiological conditions, but may be a substrate of other 
GS-X pumps, such as the canalicular multispecific organic 
anion transporter (cMOAT) [28]. cMOAT is a homologue 
of MRP that is mainly present in the canalicular membrane 
of hepatocytes where it mediates the excretion of organic an- 
ions into bile [28]. Some multidrug resistant tumor cell lines 
overexpress cMOAT,  however, suggesting that cMOAT may 
also play a role in drug resistance (Kool, M., et al., unpub- 
lished data). Transfection experiments are in progress to test 
this possibility. 
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